Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers
JCO Precision Oncology · 2026-07 · 10 (7)
DOI: 10.1200/po-25-01156 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JCO Precision Oncology, 2026-07. Verfasst von Priyanshi Shah und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Mayo Clinic Rochester, MN. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Immunotherapy, Microsatellite Instability. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMHD NIH HHS.
Abstract (Originalsprache)
PURPOSE Deficient mismatch repair/microsatellite instability (dMMR, MSI-H) in biliary tract cancers (BTCs) is observed in 1%-5% of tumors. MSI-H across solid tumors has demonstrated durable response to immune checkpoint inhibitors (ICIs) regardless of the anatomic location. Here, we describe clinical outcomes and surgical conversion of MSI-H BTC treated with ICIs. Patients and Methods We conducted a multicenter, retrospective analysis of BTC patients with dMMR/MSI-H between 2017 and 2024 at Mayo Clinic, University of Michigan, and University Hospitals Seidman Cancer Center. Outcomes of interest were surgical resection rate, rate of pathologic response, 2-year overall survival (OS; time from initiation of treatment to death/last follow-up), and time to treatment discontinuation (TTD; time from initiation of treatment to cessation because of any cause). Analyses were descriptive. RESULTS Thirty patients with MSI-H BTC were identified: 19 with cholangiocarcinoma, three with gallbladder cancer, and 8 with BTC undefined. The median age at diagnosis was 61.5 years (range, 26-86). Twenty-six (86.7%) patients had advanced stage at diagnosis. Twenty-seven patients (90%) received first-line systemic therapy, and 13 (48.1%) continued onto second line. Six patients (23.1%) were restaged to resectable from advanced disease after ICI therapy and underwent resection; all remained recurrence-free at last follow-up. Of these six patients, 3 (50%) achieved a pathologic complete response. Among those receiving first-line therapy, the median TTD was 9.9 months (95% CI, 5.7 to 14.5 months) and the 2-year OS was 73% (95% CI, 56% to 94%). CONCLUSION ICI therapy in patients with MSI-H BTC demonstrated durable response and downstaged some BTC to a resectable stage. dMMR/MSI-H should be performed up-front to guide treatment decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Oncology, Mayo Clinic Rochester, MN.
- Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN.
- Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
- Department of Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH.
- Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ.
- Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL.
ORCID-Profile: Priyanshi Shah, Vaibhav Sahai, Amit Mahipal, Nikolas Naleid, Mitesh Borad, Tanios Bekaii-Saab, Mohamad Bassam Sonbol, Umair Majeed, Hani M Babiker, Midhun Malla, Caitlyn B Conboy, Leslie A Washburn, Thorvardur R Halfdanarson, Nicole Peterson, Robert R McWilliams, Rondell P Graham, Gregory J Gores, Lewis Roberts, Fang-Shu Ou, Nguyen H Tran
Förderung
- NIMHD NIH HHS
Zitieren
APA
Shah, P., Peersen, A., Sahai, V., Mahipal, A., Naleid, N., Borad, M., Bekaii-Saab, T., Sonbol, M. B., Majeed, U., Babiker, H. M., O'Donnell, C. D. J., Malla, M., Gupta, G., Conboy, C. B., Fonkoua, L. K., Washburn, L. A., Halfdanarson, T. R., Peterson, N., McWilliams, R. R., …, & Tran, N. H. (2026). Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers. JCO Precision Oncology, 10(7). https://doi.org/10.1200/po-25-01156
Vancouver
Shah P, Peersen A, Sahai V, Mahipal A, Naleid N, Borad M, et al. Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers. JCO Precision Oncology. 2026;10(7). doi:10.1200/po-25-01156
BibTeX
@article{Shah2026,
author = {Shah, Priyanshi and Peersen, Anina and Sahai, Vaibhav and Mahipal, Amit and Naleid, Nikolas and Borad, Mitesh and Bekaii-Saab, Tanios and Sonbol, Mohamad Bassam and Majeed, Umair and Babiker, Hani M and O'Donnell, Conor D J and Malla, Midhun and Gupta, Garima and Conboy, Caitlyn B and Fonkoua, Lionel Kankeu and Washburn, Leslie A and Halfdanarson, Thorvardur R and Peterson, Nicole and McWilliams, Robert R and Carr, Ryan M and Graham, Rondell P and Starlinger, Patrick and Smoot, Rory and Warner, Susanne and Ilyas, Sumera I and Gores, Gregory J and Roberts, Lewis and Heimbach, Julie and Ou, Fang-Shu and Tran, Nguyen H},
title = {Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers},
journal = {JCO Precision Oncology},
year = {2026},
volume = {10},
number = {7},
doi = {10.1200/po-25-01156}
}
EUVIMED